Key Takeaways
-
Alvotech and Advanz have partnered to commercialize five proposed biosimilars in Europe
-
Alvotech has also just disclosed Entyvio (vedolizumab) and Keytruda (pembrolizumab) biosimilar candidates in its pipeline
-
The Advanz deal includes biosimilars to Simponi (golimumab), Entyvio (vedolizumab) and three additional undisclosed products
-
Alvotech and Stada have dropped the Simponi (golimumab) and Entyvio (vedolizumab) biosimilars as well as a Prolia/Xgeva (denosumab) rival from their partnership
-
Alvotech has also announced the termination of a co-development deal with BiosanaPharma for a biosimilar Xolair (omalizumab) candidate
-
Alvotech also provided the latest update on progress towards obtaining US FDA approval for its Humira (adalimumab) biosimilar
Alvotech has announced a five-product biosimilar commercialization deal with Advanz Pharma in Europe, capping a busy week that has also seen the biosimilars developer
One of these involved revealing biosimilar Entyvio (vedolizumab) and Keytruda (pembrolizumab) candidates as part of its pipeline, while Alvotech has also dropped three products from its existing deal with Stada and has terminated a co-development licensing deal
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?